CUMYL-CBMINACA explained

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,[1] first being identified in Germany in February 2020.[2] It is illegal in Finland.[3]

See also

Notes and References

  1. Haschimi B, Grafinger KE, Pulver B, Psychou E, Halter S, Huppertz LM, Westphal F, Pütz M, Auwärter V . 6 . New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA . Drug Testing and Analysis . 13 . 8 . 1499–1515 . August 2021 . 33788409 . 10.1002/dta.3038 . free .
  2. Web site: EU Early Warning System Situation Report. Situation report 1 . June 2020 . European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) .
  3. Web site: Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista . Government Decree on psychoactive substances banned from the consumer market . Finnish . Finlex . Finnish Ministry of Justice .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CUMYL-CBMINACA".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.